Method for inhibiting the activity of mir-155
Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
1. A method of inhibiting the activity of a microRNA comprising contacting a cell comprising the microRNA with a compound comprising an oligomeric compound, wherein:
the oligomeric compound is at least 90% complementary to miR-155 (SEQ ID NO: 1062) or a precursor thereof;
the oligomeric compound consists of 15 to 30 linked monomeric subunits; and
at least one monomeric subunit is a modified nucleoside.
2. The method of claim 1 , wherein the oligomeric compound is at least 95% complementary to miR-155 (SEQ ID NO: 1062) or a precursor thereof.
3. The method of claim 1 , wherein the oligomeric compound is 100% complementary to miR-155 (SEQ ID NO: 1062) or a precursor thereof.
4. The method of claim 1 , wherein the oligomeric compound is 100% complementary to at least an 8-nucleobase portion of miR-155 (SEQ ID NO: 1062) or a precursor thereof.
5. The method of claim 1 , wherein the oligomeric compound consists of 19 to 23 linked monomeric subunits.
6. The method of claim 1 , wherein the oligomeric compound consists of an oligonucleotide.
7. The method of claim 6 , wherein the oligonucleotide consists of 19 to 23 linked nucleosides.
8. The method of claim 1 , wherein the oligomeric compound comprises at least one modified sugar moiety.
9. The method of claim 8 , wherein the modified sugar moiety is selected from 2′-F, 2′-O-methyl, 2′-O-methoxyethyl, and a bicyclic sugar moiety.
10. The method of claim 9 , wherein the bicyclic sugar moiety comprises a 4′-CH 2 -O-2′ bridge.
11. The method of claim 1 , wherein the oligomeric compound comprises at least one modified internucleoside linkage.
12. The method of claim 11 , wherein the modified internucleoside linkage is a phosphorothioate linkage.
13. The method of claim 1 , wherein each internucleoside linkage of the oligomeric compound is a phosphorothioate linkage.
14. The method of claim 1 , wherein each monomeric subunit comprises a modified sugar moiety.
15. The method of claim 6 , wherein the oligonucleotide comprises two or more chemically distinct regions.
16. The method of claim 15 , wherein each nucleoside of the two or more chemically distinct regions is independently selected from a 2′-fluoro nucleoside, a 2′-O-methyl nucleoside, a 2′-O-methoxyethyl nucleoside, a 2′-deoxynucleoside, and a bicyclic sugar nucleoside.
17. The method of claim 15 , wherein each nucleoside of the two or more chemically distinct regions is independently selected from a 2′-deoxynucleoside and a bicyclic sugar nucleoside.
18. The method of claim 17 , wherein the bicyclic nucleoside comprises a 4′-CH 2 -O-2′ bridge.
19. The method of claim 1 , wherein the oligomeric compound comprises at least one modified nucleobase.
20. The method of claim 19 , wherein the modified nucleobase is 5-methylcytosine.
21. The method of claim 1 , wherein the oligomeric compound is attached to a conjugate group.
22. The method of claim 21 , wherein the conjugate group is cholesterol.